China biotech player Reistone raises $100m
Reistone, a novel drug developer incubated by Jiangsu Hengrui Pharmaceuticals, has raised a Series A of nearly USD 100m led by Huagai Capital.
Other investors include Yunion Healthcare Fund, Shanghai Zhangjiang Haoheng Innovative Equity Investment, Zero2IPO Industry Investment, and Hanne Capital. This is Reistone’s first external funding...
More on Greater China
Latest News
Ince leads $30m round for China’s PhiGent Robotics
Beijing-based autonomous driving solutions provider PhiGent Robotics has raised a USD30m Series A round led by Ince Capital. Previous investors such as Atypical Ventures, 5Y Capital, and GSR Ventures re-upped.
China's BlueRun $819m across US dollar, renminbi funds
China-based BlueRun Ventures has closed its third US dollar-denominated China fund and third renminbi vehicle with aggregate commitments of CNY 5.5bn (USD 819m).
Singapore's Azalea targets $754m PE-backed bond offering
Temasek Holdings-owned Azalea Investment Management is further expanding retail exposure to private equity through its latest issue of bonds – worth USD 754m in total – backed by LP interests in funds.
Hong Kong's Betatron hits $15m first close on VC fund
Hong Kong’s Betatron Venture Group has reached a first close of USD 15m on its latest fund, which will make early-stage investments across South and Southeast Asia. The target is USD 50m.